Alfuzosin Hydrochloride
Product Images NDC 54868-6329

Product Visual Gallery

This gallery contains 9 technical images submitted to the FDA as part of the official labeling for Alfuzosin Hydrochloride (NDC 54868-6329). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Physicians Total Care, Inc., these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

Bottle-30s (6329)

Alfuzosin Hydrochloride extended release tablets, 10 mg strength, in a 30 tablet package. The label shows the Physicians Total Care logo and states NDC 54868-6329. It includes instructions to use as directed by a healthcare provider and cautions against dispensing without prescription. The label also features storage instructions, lot number, and expiration date fields.*

FDA Label Image

Structure (Alfuzosin 01)

Chemical structure of Alfuzosin Hydrochloride, showing the molecular arrangement including methoxy, amine, and other functional groups along with the hydrochloride salt component.*

FDA Label Image

Figure-2 (Alfuzosin 03)

A line graph comparing mean change over days of treatment between placebo and alfuzosin groups. The x-axis represents days of treatment (0, 28, 56, 84), and the y-axis shows mean change values. Data points for placebo (N=167) are shown with triangles, and alfuzosin (N=170) with squares, indicating a greater mean change reduction in the alfuzosin group over time, with statistical significance noted at p < 0.001.*

FDA Label Image

Figure-3 (Alfuzosin 04)

A line graph comparing mean change over days of treatment between two groups: placebo (N=152) and Alfuzosin (N=137). The x-axis represents days of treatment (0, 28, 56, 84), and the y-axis shows mean change in an unspecified measure, with Alfuzosin consistently showing greater reduction than placebo through day 84, indicating statistical significance (p < 0.01).*

FDA Label Image

Figure-4 (Alfuzosin 05)

Line graph comparing mean change over days of treatment between Alfuzosin and placebo groups. The x-axis displays treatment days (0, 28, 56, 84) and the y-axis shows mean change values. Alfuzosin group shows a greater reduction over time compared to placebo, with statistically significant difference at day 84 (p < 0.01).*

FDA Label Image

Figure-5 (Alfuzosin 06)

A line graph depicting the mean change in mL/s over days of treatment for Alfuzosin versus placebo groups. The x-axis represents days of treatment (0, 28, 56, 84) and the y-axis shows mean change in mL/s. Alfuzosin shows a significant increase maintained through day 84, whereas placebo remains near baseline.*

FDA Label Image

Figure-6 (Alfuzosin 07)

A line graph comparing mean change in a measured variable (mL/s) over 84 days of treatment between Alfuzosin and placebo groups. The x-axis represents days of treatment (0, 14, 28, 56, 84), and the y-axis shows mean change values. Alfuzosin group shows greater improvement than placebo throughout the study period.*

FDA Label Image

Figure-7 (Alfuzosin 08)

A line graph comparing the mean change in mL/s over days of treatment between Alfuzosin and placebo groups. The x-axis shows days of treatment (0, 14, 28, 56, 84), and the y-axis shows mean change in mL/s, with Alfuzosin group showing a higher increase than placebo. Statistical significance noted with p < 0.001 at day 84.*

FDA Label Image

Figure-1 (Uroxatral Image02)

A line graph depicting Alfuzosin plasma concentration (ng/mL) over a 24-hour period under fed and fasted conditions. The x-axis represents time in hours, and the y-axis shows Alfuzosin plasma concentration. Two lines with error bars illustrate concentration differences between fed (higher peak) and fasted states.*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.